- Home
- NMI vs CRBU Comparison
NMI vs CRBU Comparison
Compare NMI & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMI | CRBU |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.6M | 138.3M |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NMI | CRBU |
|---|---|---|
| Price | $9.27 | $1.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $11.86 |
| AVG Volume (30 Days) | 49.0K | ★ 1.1M |
| Earning Date | 01-01-0001 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $128.04 |
| Revenue Next Year | N/A | $17.09 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.10 | $1.17 |
| 52 Week High | $11.28 | $3.53 |
Technical Indicators
Market Signals| Indicator | NMI | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 25.23 | 28.17 |
| Support Level | N/A | N/A |
| Resistance Level | $10.97 | $1.74 |
| Average True Range (ATR) | 0.18 | 0.05 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 21.25 | 0.00 |
Price Performance
Historical ComparisonAbout NMI Nuveen Municipal Income Fund Inc.
Nuveen Municipal Income Fund Inc is a diversified, closed-end management investment company. The Fund's investment objective is to provide a high level of current income exempt from federal income tax, which it seeks to achieve by investing mainly in a diversified portfolio of tax-exempt municipal obligations.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.